The panel discuss the work that is being done to develop combination therapies for myeloma which take advantage of both immunotherapies and targeted therapies.
The most notable of these new therapies are ipilimumab and vemurafenib and the pharmaceutical companies Roche and Bristol-Myers Squibb (BMS) are working together to develop effective combinations of these two agents. In addition to this, early results of research into MEK inhibitor and BRAF inhibitor combinations have shown a reduced toxicity profile and promising levels of efficacy.